Multiple Sclerosis Clinical Trial

Videofluoroscopic Swallowing Study (VFSS)

Summary

The study procedure of simultaneous VFSS and DDS measurement will be completed in one day and the subject will be followed within 2 business days after the study procedure to monitor for adverse events.

View Full Description

Full Description

DDS signals and VFSS will be recorded simultaneously (for the same bolus) using barium contrast agent stimuli prepared in three consistencies: thin, mildly-thick and moderately-thick. Subjects will undergo VFSS with simultaneous DDS using up to 5 boluses of thin barium stimulus ("THIN-Ba"), and up to 4 boluses of barium thickened to mildly ("MILD-Ba") thick and up to 4 boluses of moderately ("MODERATE-Ba") thick barium consistencies using Resource Thicken Up Clear Nestlé Health Science (TUC). 4, 3 and 3 boluses for THIN-Ba, MILD-Ba and MOD-Ba will be analyzed using the classifier algorithms for sensitivity/specificity results. According to the exploratory trial, VFSS data for safety or efficiency can be missing for up to 14% boluses due to quality of VFSS recording. To compensate for potential losses of boluses due to missing gold standard (VFSS) data, 5, 4 and 4 boluses will be collected for the three consistencies respectively . The DDS signals will be sent to a dedicated application software installed at the CRO, which interprets the acceleration data and displays the examination result. The VFSS recording will be sent to CRO and provided for blinded assessment by the independent central VFSS laboratory.The study procedure of simultaneous VFSS and DDS measurement will be completed in one day and the subject will be followed within 2 business days after the study procedure to monitor for adverse events.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adult subjects (over 18 years of age)
Hospitalized subjects or outpatients identified as at risk of oropharyngeal dysphagia (using local practice)

Patients belong to one of the following groups:

Stroke patients
Traumatic brain injury
Parkinson Disease (PD) stage III or higher by Hoehn and Yahr scale
Multiple Sclerosis (MS) above age 60
Alzheimer Disease (AD) or other Dementia
Other medically complex hospitalized subjects not covered by the exclusion criteria and identified as at risk of dysphagia
Subject is able to comply with VFSS protocol to diagnose dysphagia
Subject is able to give voluntary, written informed consent to participate in the clinical investigation and from whom consent has been obtained / or a consultee has consented on he subjects behalf in line with nationally agreed guidelines concerning adults unable to consent for themselves.

Exclusion Criteria:

Presence of nasogastric / nasojejunal feeding tube at the time of VFSS test
Currently has a tracheostomy, or has had a tracheostomy in the past year
Had posterior cervical spine surgery and/or carotid endarterectomy in the last 6 months
Had significant surgery to the mouth and/or neck, for example resection for oral or pharyngeal cancer, radical neck dissection, anterior cervical spine surgery, orofacial reconstruction, pharyngoplasty, or thyroidectomy. Routine tonsillectomy and/or adenoidectomy are not excluded
Experienced non-surgical trauma to the neck (e.g., knife wound) resulting in musculoskeletal or nerve injury in the neck.
Received radiation or chemotherapy to the oropharynx or neck for cancer.
Allergy to oral radiographic contrast media (specifically barium)
Distorted oropharyngeal anatomy (e.g. pharyngeal pouch)
Cognitive impairment that prevents them from being able to comply with study instructions and procedures
Known to be pregnant at the time of enrollment
Currently has significant facial hair at the location of sensor adherence and are unwilling/unable to be shaved
Any patients the local investigator finds that participation would not be in patients' best interest

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

452

Study ID:

NCT03387267

Recruitment Status:

Terminated

Sponsor:

Société des Produits Nestlé (SPN)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 13 Locations for this study

See Locations Near You

Rancho Research Institute, Rancho Los Amigos National Rehabilitation Center
Downey California, 90242, United States
University of Colorado Denver
Aurora Colorado, 80045, United States
Medstar Rehabilitation Hospital
Washington District of Columbia, 20010, United States
Shirley Ryan AbilityLab
Chicago Illinois, 60611, United States
Marionjoy Rehabilitation Hospital
Wheaton Illinois, 60187, United States
Kentucky Clinic
Lexington Kentucky, 40536, United States
Boston Medical Center
Boston Massachusetts, 02118, United States
Henry Ford Health System
Detroit Michigan, 48202, United States
New York Presbyterian/Weill Cornell Medical Center
New York New York, 10021, United States
New York Presbyterian Hospital/Columbia University Medical Center
New York New York, 10032, United States
The Burke Medical Research Institute
White Plains New York, 10605, United States
The Cleveland Clinic Foundation
Cleveland Ohio, 44195, United States
Helsinki University Central Hospital
Helsinki , 00029, Finland

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

452

Study ID:

NCT03387267

Recruitment Status:

Terminated

Sponsor:


Société des Produits Nestlé (SPN)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider